Ratna Danda, MD
Nephrology · Desoto, TXNPI 1467481382
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 331 payments — averaging $25.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Bayer$704
- OPKO Pharmaceuticals, LLC$494
- GSK$482
- Otsuka America Pharmaceutical, Inc.$466
- plus $3K from 31 others
Across 76 payments — averaging $4527.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$208K
- GSK$136K
What the payments were for
- Food & beverage$8,45899%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 52 | $1,671 |
| Amgen(2 entities) | 53 | $1,442 |
| Bayer | 29 | $704 |
| OPKO Pharmaceuticals, LLC | 34 | $494 |
| GSK | 15 | $482 |
| Otsuka America Pharmaceutical, Inc. | 14 | $466 |
| Vifor Pharma, Inc. | 18 | $464 |
| Akebia Therapeutics Inc | 27 | $453 |
| Aurinia Pharma U.S., Inc. | 8 | $356 |
| Calliditas Therapeutics US Inc. | 6 | $327 |
| Fresenius USA Marketing, Inc. | 15 | $310 |
| Travere Therapeutics, Inc. | 8 | $165 |
| Baxter Healthcare | 2 | $137 |
| Boehringer Ingelheim | 6 | $136 |
| Mallinckrodt Hospital Products Inc. | 4 | $131 |
| Lilly USA, LLC | 6 | $124 |
| Nxstage Medical, Inc. | 1 | $73 |
| Novartis | 4 | $67 |
| Shire North American Group Inc | 4 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| Novo Nordisk | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Ardelyx, Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Renalytix AI, Inc. | 2 | $32 |
| Cormedix Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Medtronic | 1 | $15 |
| Avenu Medical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,554 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $104,824 |
| JardianceEmpagliflozin | 50 | $34,270 |
| KerendiaFinerenone | 34 | $29,165 |
| AuryxiaFerric Citrate | 15 | $19,904 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $15,458 |
| ProsolParenteral Amino Acid 20% No.1 | 37 | $8,250 |
| Sevelamer Carbonate | 27 | $5,091 |
| Bumetanide | 29 | $2,288 |
| Clonidine | 25 | $1,808 |
| Nifedipine ErNifedipine | 76 | $1,734 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,649 |
| Calcium Acetate | 19 | $1,105 |
| Hydralazine Hcl | 80 | $1,064 |
| Losartan Potassium | 163 | $984 |
| Metolazone | 26 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,671 | $120,282153 claims |
| Boehringer IngelheimJardiance | $136 | $34,27050 claims |
| BayerKerendia | $704 | $29,16534 claims |
| Akebia Therapeutics IncAuryxia | $453 | $19,90415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Desoto
- Samir NangiaDesoto$127K
- Parin MakadiaDesoto$58K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.